Abstract
Clinical trials utilizing predictive biomarkers have become a research focus in personalized medicine. We investigate the effects of biomarker misclassification on the design and analysis of stratified biomarker clinical trials. For a variety of inference problems including marker-treatment interaction in particular, we show that marker misclassification may have profound adverse effects on the coverage of confidence intervals, power of the tests, and required sample sizes. For each inferential problem, we propose methods to adjust for the classification errors.
| Original language | English |
|---|---|
| Pages (from-to) | 3100-3113 |
| Number of pages | 14 |
| Journal | Statistics in Medicine |
| Volume | 33 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - 15 Aug 2014 |
Keywords
- Biomarkers
- Classification error
- Correction for error
- Personalized medicine
- Power and sample size
- Prevalence
- Randomized controlled clinical trials
- Sensitivity and specificity
ASJC Scopus subject areas
- Epidemiology
- Statistics and Probability
Fingerprint
Dive into the research topics of 'Adjusting for misclassification in a stratified biomarker clinical trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver